What is it?
GHRP-6 is a synthetic peptide that activates a ghrelin-related signal and can prompt the body to release more of its own growth hormone.
Gathering the record
Loading the next view…
Relay is organizing the evidence and source boundaries.
Gathering the record
Relay is organizing the evidence and source boundaries.
Synthetic hexapeptide growth hormone secretagogue receptor agonist
GHRP-6 is a synthetic ghrelin-receptor agonist studied mainly in small acute human physiology experiments. It can trigger GH release, but there is no controlled evidence establishing muscle gain, fat loss, recovery, improved sleep, or longevity.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
GHRP-6 is a synthetic peptide that activates a ghrelin-related signal and can prompt the body to release more of its own growth hormone.
Researchers have used it to study short-term hormone physiology, absorption, and the relationship between ghrelin signaling and the body's natural growth-hormone rhythm. Small studies also examined oral and overnight exposure.
Peer-reviewed human experiments show acute growth-hormone release and describe short-term pharmacokinetics. The studies are small, use different routes, and mainly measure hormone changes rather than health or performance outcomes. One-night research does not support a simple sleep-benefit claim.
Long-term benefit, appetite and glucose effects, endocrine nonselectivity, desensitization, repeated-use safety, body composition, recovery, sustained sleep outcomes, and product quality remain unresolved. No approved therapeutic use exists.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
A peer-reviewed early human study administered GHRP-6 to healthy men to characterize short-term exposure and elimination.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
PK, endocrine, and nocturnal physiology have been studied.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Confidence is low for untested therapeutic outcomes.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The study included nine healthy men and measured pharmacokinetics rather than a clinical outcome. Intravenous single-exposure findings do not establish chronic subcutaneous use, therapeutic benefit, or product equivalence. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
Several small peer-reviewed human pharmacology and endocrine studies consistently demonstrate acute exposure and GH release.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Long-term benefit and safety, appetite and metabolic effects, endocrine nonselectivity, desensitization, product quality, and any body-composition, recovery, or sleep outcome.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
The response depends partly on endogenous GHRH physiology.
A nine-person IV study estimated an elimination half-life around 2.5 hours.
The study did not establish improved growth outcomes.
A small study found route-dependent hormone and EEG changes, not durable sleep benefit.
The record is limited to small physiology studies.
Mechanisms
GHRP-6 is a synthetic hexapeptide agonist at GHSR1a. Human studies show rapid pharmacokinetics and acute GH release, including oral challenge research in children with short stature. Blocking endogenous GHRH markedly reduces its GH response, demonstrating dependence on intact hypothalamic-pituitary physiology. Nocturnal experiments found route-dependent GH, ACTH, cortisol, and sleep-EEG effects rather than a clear sleep benefit. No FDA-approved product, modern long-term outcomes program, or controlled body-composition benefit was identified.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Placebo-controlled nocturnal administration study
Healthy volunteers
GHRP-6 altered endocrine measures and sleep architecture in a route-dependent manner without demonstrating a simple sleep benefit.
Study administration: GHRP-6 by different routes or placebo
Limitations: Small one-night studies cannot define chronic sleep effects.
Controlled blockade study
Healthy adults
Blocking endogenous GHRH markedly reduced the response to GHRP-6.
Study administration: GHRP-6 with or without endogenous GHRH blockade
Limitations: Acute physiology does not establish clinical outcomes.
Open-label intravenous pharmacokinetic study
Nine healthy men
GHRP-6 showed rapid distribution and an estimated terminal elimination half-life around 2.5 hours.
Study administration: Intravenous GHRP-6
Limitations: Nine participants and intravenous exposure do not establish chronic subcutaneous outcomes or product equivalence.
Acute oral challenge study
Children with short stature
Oral GHRP-6 elicited acute GH responses in the studied children.
Study administration: Oral GHRP-6
Limitations: Hormone release does not establish improved linear growth or long-term safety.
Safety snapshot
No source-qualified adverse-event pattern is represented in the current record.
Evidence boundaryHuman exposure is present, but the record is not detailed enough to characterize a reliable adverse-event pattern.
The current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
No source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryNot FDA approved — small acute human physiology studies Long-term benefit and safety, appetite and metabolic effects, endocrine nonselectivity, desensitization, product quality, and any body-composition, recovery, or sleep outcome.
The current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2013-01-01 · PMID 23099431 · DOI 10.1016/j.ejps.2012.10.006
1999-05-01 · PMID 10336729 · DOI 10.1046/j.1365-2826.1999.00364.x
1998-04-01 · PMID 9543138 · DOI 10.1210/jcem.83.4.4711
1995-11-01 · PMID 7581965 · DOI 10.1530/eje.0.1330425